Report cover image

Anticoagulants Market by Route of Administration (Injectable Anticoagulants, Oral Anticoagulants), Anticoagulant Drug (Betrixaban, Dabigatran, Edoxaban or Rivaroxaban), Drug Class, Application - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 182 Pages
SKU # IRE18417869

Description

Anticoagulants Market by Route of Administration (Injectable Anticoagulants, Oral Anticoagulants), Anticoagulant Drug (Betrixaban, Dabigatran, Edoxaban or Rivaroxaban), Drug Class, Application - Global Forecast 2024-2030


The Anticoagulants Market size was estimated at USD 40.20 billion in 2023 and expected to reach USD 44.24 billion in 2024, at a CAGR 10.14% to reach USD 79.07 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anticoagulants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anticoagulants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulants Market, highlighting leading vendors and their innovative profiles. These include Akebia Therapeutics, Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Athenex, Inc., Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, Eisai Co., Ltd., Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulants Market to forecast the revenues and analyze trends in each of the following sub-markets:

Route of Administration

Injectable Anticoagulants
  • Oral Anticoagulants
  • Anticoagulant Drug

    Betrixaban
  • Dabigatran
  • Edoxaban or Rivaroxaban
  • Eliquis
  • Drug Class

    DTIs
  • Factor XA Inhibitors
  • Heparin
  • Vitamin K Antagonists
  • Application

    Atrial fibrillation & Heart Attack
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Stroke
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Anticoagulants Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anticoagulants Market?
    3. What are the technology trends and regulatory frameworks in the Anticoagulants Market?
    4. What is the market share of the leading vendors in the Anticoagulants Market?
    5. Which modes and strategic moves are suitable for entering the Anticoagulants Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    182 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Anticoagulants Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Increasing prevalence of venous thromboembolism and cardiovascular disorders
    5.1.1.2. Rising number of anticoagulation stewardship programs
    5.1.1.3. Increasing acceptance of novel oral anticoagulants
    5.1.2. Restraints
    5.1.2.1. Stringent regulations related to drug dosage and clinical approvals
    5.1.3. Opportunities
    5.1.3.1. Introduction of novel anticoagulation therapeutics and increasing R&D investments
    5.1.3.2. Use of AI and ML to predict anticoagulation control
    5.1.4. Challenges
    5.1.4.1. Side-effects and complications associated with the usage of oral anticoagulants
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Anticoagulants Market, by Route of Administration
    6.1. Introduction
    6.2. Injectable Anticoagulants
    6.3. Oral Anticoagulants
    7. Anticoagulants Market, by Anticoagulant Drug
    7.1. Introduction
    7.2. Betrixaban
    7.3. Dabigatran
    7.4. Edoxaban or Rivaroxaban
    7.5. Eliquis
    8. Anticoagulants Market, by Drug Class
    8.1. Introduction
    8.2. DTIs
    8.3. Factor XA Inhibitors
    8.4. Heparin
    8.5. Vitamin K Antagonists
    9. Anticoagulants Market, by Application
    9.1. Introduction
    9.2. Atrial fibrillation & Heart Attack
    9.3. Deep Vein Thrombosis
    9.4. Pulmonary Embolism
    9.5. Stroke
    10. Americas Anticoagulants Market
    10.1. Introduction
    10.2. Argentina
    10.3. Brazil
    10.4. Canada
    10.5. Mexico
    10.6. United States
    11. Asia-Pacific Anticoagulants Market
    11.1. Introduction
    11.2. Australia
    11.3. China
    11.4. India
    11.5. Indonesia
    11.6. Japan
    11.7. Malaysia
    11.8. Philippines
    11.9. Singapore
    11.10. South Korea
    11.11. Taiwan
    11.12. Thailand
    11.13. Vietnam
    12. Europe, Middle East & Africa Anticoagulants Market
    12.1. Introduction
    12.2. Denmark
    12.3. Egypt
    12.4. Finland
    12.5. France
    12.6. Germany
    12.7. Israel
    12.8. Italy
    12.9. Netherlands
    12.10. Nigeria
    12.11. Norway
    12.12. Poland
    12.13. Qatar
    12.14. Russia
    12.15. Saudi Arabia
    12.16. South Africa
    12.17. Spain
    12.18. Sweden
    12.19. Switzerland
    12.20. Turkey
    12.21. United Arab Emirates
    12.22. United Kingdom
    13. Competitive Landscape
    13.1. FPNV Positioning Matrix
    13.2. Market Share Analysis, By Key Player
    13.3. Competitive Scenario Analysis, By Key Player
    14. Competitive Portfolio
    14.1. Key Company Profiles
    14.1.1. Akebia Therapeutics, Inc.
    14.1.2. Aspen Pharmacare Holdings Limited
    14.1.3. AstraZeneca PLC
    14.1.4. Athenex, Inc.
    14.1.5. Bayer AG
    14.1.6. C.H. Boehringer Sohn AG & Ko. KG
    14.1.7. Eisai Co., Ltd.
    14.1.8. Eli Lilly and Company
    14.1.9. Johnson & Johnson
    14.1.10. LEO Pharma A/S
    14.1.11. Novartis AG
    14.1.12. Pfizer Inc.
    14.1.13. Sanofi S.A.
    14.1.14. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
    14.1.15. Teva Pharmaceutical Industries Ltd.
    14.1.16. Viatris Inc.
    14.2. Key Product Portfolio
    15. Appendix
    15.1. Discussion Guide
    15.2. License & Pricing
    FIGURE 1. ANTICOAGULANTS MARKET RESEARCH PROCESS
    FIGURE 2. ANTICOAGULANTS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANTICOAGULANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANTICOAGULANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANTICOAGULANTS MARKET DYNAMICS
    FIGURE 7. ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
    FIGURE 8. ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2030 (%)
    FIGURE 10. ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
    FIGURE 12. ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
    FIGURE 14. ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 16. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 18. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 24. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us